ABVC BioPharma closes $3.39 million discounted convertible note private placement
ABVC BioPharma sold senior convertible promissory notes with a principal amount of $4,106,060 at a 17.5% original‑issue discount, generating $3.39 million in gross proceeds. The notes mature on June 30 2027 and will convert into common stock at 85% of the three‑day average VWAP, subject to a floor price. Proceeds will fund working capital, subsidiary operations and a $625,000 settlement with Lind Global Fund II. WallachBeth Capital acted as the placement agent.
Why it matters
The company expects the net proceeds to support its cash needs and settle the Lind dispute, while the convertible feature may lead to future equity dilution for shareholders. The settlement payment clears a pending litigation claim, removing a contingent liability.
Key facts
- 1The offering raised approximately $3.39 million in gross proceeds before fees. prnewswire.com
- 2The notes have an aggregate principal amount of $4,106,060. prnewswire.com
- 3The notes carry a 17.5% original‑issue discount. prnewswire.com
- 4Maturity is set for June 30 2027. prnewswire.com
- 5Conversion price is 85% of the three‑day average VWAP, with a floor price provision. prnewswire.com
- 6ABVC will use $625,000 of the proceeds to settle a claim with Lind Global Fund II. prnewswire.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.